Icon

LORBRENA - (25MG, 100MG)

LORLATINIB None
25MG, 100MG
Less Than $1000 mn
None None
None None
None None
LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Yes
LORBRENA Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.